Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

Uniqure NV

Healthcare US QURE

27.0USD
0.55(2.08%)

Last update at 2026-06-08T20:00:00Z

Day Range

26.7827.76
LowHigh

52 Week Range

3.7319.18
LowHigh

Fundamentals

  • Previous Close 26.45
  • Market Cap750.05M
  • Volume760389
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-157.58400M
  • Revenue TTM20.20M
  • Revenue Per Share TTM0.41
  • Gross Profit TTM -125.12600M
  • Diluted EPS TTM-4.38

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Income before tax -237.12700M -306.55700M -128.25900M 332.81M -141.44300M
Minority interest - - - - -
Net income -239.55600M -308.47800M -126.78900M 329.59M -125.02400M
Selling general administrative 50.68M 75.36M 55.06M 57.17M 42.58M
Selling and marketing expenses 1.98M - - - -
Gross profit 8.79M 2.21M 103.14M 499.03M -84.88600M
Reconciled depreciation 12.64M 10.04M 8.54M 7.30M 10.65M
Ebit -173.38600M -265.00000M -116.55500M 311.70M -137.61800M
Ebitda -160.74500M -253.10000M -108.01800M 319.00M -126.97000M
Depreciation and amortization 12.64M 11.90M 8.54M 7.30M 10.65M
Non operating income net other - - - 29.66M -12.19200M
Operating income -184.29400M -282.87100M -143.15900M 310.62M -125.42600M
Other operating expenses 197.71M 298.71M 249.64M 213.38M 162.94M
Interest expense 63.74M 41.56M 11.70M 7.47M 3.83M
Tax provision 2.43M -1.32000M -1.47000M 3.22M -16.41900M
Interest income 21.41M 12.88M 0.61M 0.16M 0.94M
Net interest income -42.32600M -16.38600M -11.09500M -7.31200M -2.88700M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 2.43M 1.92M -1.47000M 3.22M -16.41900M
Total revenue 27.12M 15.84M 106.48M 524.00M 37.51M
Total operating expenses 193.09M 285.09M 246.30M 188.41M 162.94M
Cost of revenue 18.33M 13.63M 3.34M 24.98M 122.40M
Total other income expense net -52.83300M -23.68600M 14.90M 22.19M -16.01700M
Discontinued operations - - - - -
Net income from continuing ops -239.55600M -228.46500M -126.78900M 329.59M -125.02400M
Net income applicable to common shares - - -126.78900M 329.59M -125.02400M
Preferred stock and other adjustments - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Total assets 556.54M 831.69M 704.96M 809.18M 340.39M
Intangible assets 71.04M 60.48M 58.78M 62.69M 3.36M
Earning assets - - - - -
Other current assets 16.89M 2.65M 2.81M 2.67M 3.02M
Total liab 563.29M 624.02M 228.96M 213.40M 96.49M
Total stockholder equity -6.75200M 207.67M 476.01M 595.78M 243.91M
Deferred long term liab - - - - -
Other current liab 29.23M 29.65M 56.55M 28.49M 15.96M
Common stock 2.94M 2.88M 2.84M 2.80M 2.71M
Capital stock 2.94M 2.88M 2.84M 2.80M 2.71M
Retained earnings -1129.96500M -890.40900M -581.93100M -455.14200M -784.73100M
Other liab - - 18.53M 46.69M 3.14M
Good will 22.41M 26.38M 25.58M 27.63M 0.54M
Other assets - - 20.59M 21.54M 45.25M
Cash 158.93M 241.36M 228.01M 556.26M 244.93M
Cash and equivalents - - - - -
Total current liabilities 40.05M 73.67M 75.92M 36.76M 27.33M
Current deferred revenue - 29.10M - - 2.08M
Net debt -92.86900M -102.95100M -85.12000M -420.53200M -173.38800M
Short term debt 3.60M 8.34M 8.38M 5.77M 5.52M
Short long term debt - - - - -
Short long term debt total 66.06M 138.41M 142.89M 135.72M 71.54M
Other stockholder equity 1173.07M 1148.75M 1113.39M 1076.97M 1016.02M
Property plant equipment - - 83.26M 43.51M 32.33M
Total current assets 390.29M 651.85M 476.77M 628.24M 258.91M
Long term investments 27.46M 0.00000M 39.98M - -
Net tangible assets - - 391.65M 595.78M 243.91M
Short term investments 208.59M 376.53M 124.83M - -
Net receivables 5.88M 4.19M 102.38M 58.77M 6.62M
Long term debt 51.32M 101.75M 102.79M 100.96M 35.62M
Inventory 0.00000M 12.02M 6.92M 10.54M 4.34M
Accounts payable 7.23M 6.59M 10.98M 2.50M 3.77M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -52.80000M -53.55300M -58.29100M -28.85600M 9.91M
Additional paid in capital - - - - -
Common stock total equity - - - 2.80M 2.71M
Preferred stock total equity - - - - -
Retained earnings total equity - - - -455.14200M -784.73100M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 1.40M 5.36M 6.06M 5.90M 2.75M
Deferred long term asset charges - - - - -
Non current assets total 166.25M 179.84M 228.19M 180.94M 81.48M
Capital lease obligations 14.74M 36.66M 40.10M 34.76M 35.93M
Long term debt total - - - - -
Breakdown 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Type yearly yearly yearly yearly yearly
Date 2024-12-31 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Investments 162.97M -433.46000M -182.73400M -67.38700M -9.48400M
Change to liabilities - - 9.24M 8.48M 0.50M
Total cashflows from investing activities - - -182.73400M -67.38700M -9.48400M
Net borrowings - - - 62.49M 62.49M
Total cash from financing activities -59.48600M 362.72M 1.45M 94.86M 7.44M
Change to operating activities - - 3.38M 9.20M 3.20M
Net income -239.55600M -308.47800M -126.78900M 329.59M -125.02400M
Change in cash -84.21500M 13.37M -328.18000M 311.67M -133.04600M
Begin period cash flow 244.54M 231.17M 559.35M 247.68M 380.73M
End period cash flow 160.33M 244.54M 231.17M 559.35M 247.68M
Total cash from operating activities -182.72800M -145.92900M -145.06000M 287.96M -134.82800M
Issuance of capital stock 2.12M 0.86M 1.45M 30.90M -0.29500M
Depreciation 12.64M 11.90M 8.54M 7.30M 10.65M
Other cashflows from investing activities 174.66M - -163.14600M -49.94900M -2.21300M
Dividends paid - - - - -
Change to inventory 2.42M -6.74000M -6.92400M -6.92400M 6.97M
Change to account receivables -2.24300M -1.32300M -4.08300M -3.95900M -6.96700M
Sale purchase of stock - - - 32.36M 7.44M
Other cashflows from financing activities -8.55900M 362.41M -182.73400M 32.36M -9.48400M
Change to netincome - - 16.58M -5.29000M 36.56M
Capital expenditures 3.37M 7.15M 17.69M 17.44M 9.48M
Change receivables - - - - -
Cash flows other operating - - - -52.11600M -46.86300M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - 315.43M -136.86800M
Change in working capital -3.94400M 81.12M -43.38400M -50.48200M -6.46900M
Stock based compensation 22.26M 35.09M 34.20M 25.64M 21.83M
Other non cash items 19.50M 32.51M -16.15800M -27.29200M -19.39500M
Free cash flow -186.09600M -153.08300M -162.74800M 270.52M -144.31200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
QURE
Uniqure NV		 0.55 2.08% 27.00 - 27.93 37.13 22.27 20.16 0.99
NVO
Novo Nordisk A/S		 -1.94 4.52% 41.02 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.11 4.87% 41.25 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -3.87 0.87% 442.96 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 -24.11 3.79% 611.34 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.

Uniqure NV

Paasheuvelweg 25, Amsterdam, Netherlands, 1105 BP

Key Executives

Name Title Year Born
Mr. Matthew Craig Kapusta CEO & Exec. Director 1972
Mr. Christian Klemt CFO, Principal Financial Officer & GM of Amsterdam Site 1973
Mr. Pierre Caloz Chief Operating Officer NA
Dr. Alexander E. Kuta Ph.D. Exec. VP of Quality & Regulatory Affairs 1960
Dr. Ricardo Dolmetsch Ph.D. Pres of R&D 1969
Prof. Hugo Katus Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany NA
Mr. David Cerveny Chief Legal Officer, Gen. Counsel & Sec. 1967
Dr. Tamara Tugal Ph.D., MBA Bus. Devel. Director NA
Ms. Erin Boyer Chief People & Culture Office NA
Ms. Maria E. Cantor Chief Corp. Affairs Officer 1968

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.